Skip to main content
. 2020 Feb 4;13:247–256. doi: 10.2147/DMSO.S230684

Table 3.

Studies That Investigated Endothelial Function in Patients Treated with Bariatric Surgery

Study Cases
(n)
Controls
(n)
BMI
(kg/m2)
Inclusion Criteria Exclusion Criteria Procedure Exam FMD (%) Follow-Up
Before Surgery After Surgery
Williams et al,24 2005 8 9 52.2 (50.3–55.9);
median (IQR)
_ Cigarette smoking,
diabetes, CKD
GB FMD
GTN
5.3
(3.8–7.0)
10.2
(7.6–13.3)
(P = 0.01)
6 months
Sturm et al,30 2009 37 _ 42.4 ± 3.9 BMI > 40.0
or >35.0 +
comorbidities
Diabetes, hypertension, CVD, secondary obesity
lipid lowering or antipsychotic medication, alcohol > 20 g/day
GBP (n=8) or GB (n=29) FMD
GTN
c-IMT
5.8 ± 3.2 9.0 ± 2.9
(P <0.001)
18 months
Lind et al,15 2009 19 19
(without obesity)
43.8 ± 3.1 cases
23.1±2.0 controls
Caucasian individuals ND GBP FMD
PWV
7.9 ± 6.4 8.5 ± 6.2 (1 month)
9.3 ± 5.9 (1 year)
(P= NS vs pre-surgical procedure)
1 year
Bigornia et al,28 2010 43
(17 BS +
26 diet)
_ 45 ± 9 _ CKD, CHF, stroke GBP or GB FMD
GTN
6.8 ± 4.2
(cases with weight loss n =29, of which n=17 BS)
10.0 ± 4.7
(P= 0.013 vs cases with no weight loss)
1 year
Brethauer et al,16 2011 15 _ 48.1 ± 5.3 BMI >40.0
or >35.0 +
comorbidities; age (18–75 years)
Diabetes, OSAS,
Hypertension
GBP FMD
GTN
2.6 ± 2.0
(GTN
20.5 ± 6.7)
4.4 ± 3.4
(P =0.21)
(GTN
23.6 ± 6.4)
(P =0.047)
6 months
Saleh et al,25 2012 47 _ 47.1 ± 5.5 BMI >40.0,
age (18–65 years)
Diabetes, use of thyroid hormones, CKD, CHF,
atrial fibrillation
GBP FMD
GTN
c-IMT
7.4 ± 5.8 18.9 ± 7.4
(P <0.001)
10 months
Nerla et al,26 2012 50 20
(no on diet)
47.1 ± 8.4 _ CKD, inflammatory bowel diseases, asthma, alcohol use disorder GBP (n=47) or
BPD (n=3)
FMD
GTN
5.9 ± 2.7 8.8 ± 2.4
(P < 0.01)
3 months
Tschoner et al,27 2013 52 (36 assessed for FMD) _ 43.6 ± 4.9 BMI > 40.0
or >35.0 +
comorbidities
Diabetes, CKD, hypertension, acute or chronic liver diseases, alcohol use disorder GBP
(n=42) or GB (n=10)
FMD
c-IMT
5.2 ± 3.3 6.6 ± 3.4
(P= 0.001)
5 years
Flores et al,17 2014 33 _ 45 Age 18–65 years,
BMI >40.0
or >35.0 +
comorbidities, normal renal function, hypertension on <3 medications
Secondary hypertension or established CVD GBP (n=18) or sleeve gastrectomy (n=15) FMD 9 ± 7 8 ± 6
(P= NS vs pre-surgical procedure)
1 year
Tromba et al,31 2017 45 _ 44.3 ± 4.6 BMI >30.0–57.7 Diabetes and CVD Sleeve gastrectomy FMD
c-IMT
3 (median value) 10 (median value, both at 3 and 6 months)
(P= 0.001 3 months vs baseline; P= NS 6 months vs 3 months)
6 months
Tarzia et al,29 2017 19 _ 47.7 ± 6.2 _ CKD, inflammatory bowel diseases, asthma, alcohol use disorder GBP (n=18) or BPD (n=1) FMD
c-IMT
6.4 ± 2.8 9.5 ± 2.6 (3 months;
P< 0.01)
8.2 ± 1.7 (4 years;
P< 0.05)
(overall P< 0.01)
4 years
de Assunção Machado et al,32 2018 56 (28 with OSAS and 28 without OSAS) _ 41.6 ± 3 (no OSAS)
43.2 ± 5.5 (OSAS)
Age ≥ 16 years, BMI > 40.0
or
BMI >35.0 +
comorbidities, with or without OSAS
Hyperthyroidism (TSH <0.01), neoplasms or immunosuppressive diseases,
Cushing’s syndrome or chronic use of corticosteroids,
COPD, diabetic nephropathy, RA, diabetes, smokers, normal endothelial function
GBP FMD
GTN
3.4 ± 2.9 (no OSAS)
3.2 ± 2.2 (OSAS)
14.8 ± 4.6 (no OSAS)
11.1 ± 3.6 (OSAS)
(P <0.001)
6 months

Abbreviations: BMI, body mass index; BPD, biliopancreatic diversion; CKD, chronic kidney disease; CHF, chronic heart failure; c-IMT, carotid intima-media thickness; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FMD, flow-mediated dilation; GB, adjustable gastric banding; GBP, gastric by-pass; GTN, glyceryl-trinitrate dilation of the brachial artery; ND, not determined; NS, not significant; OSAS, obstructive sleep apnea syndrome; PWV, pulse-wave velocity; RA, rheumatoid arthritis.